Washington is currently home to 1780 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
NCT03970096
Recruiting
This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cell... Read More
Gender:
All
Ages:
Between 1 year and 60 years
Trial Updated:
05/28/2024
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndrome
Register for Updates
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)
NCT06383390
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease.
Gender:
All
Ages:
45 years and above
Trial Updated:
05/27/2024
Locations: Eastside Research Associates, Redmond, Washington
Conditions: Overweight and Obesity
Register for Updates
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
NCT06340854
Recruiting
This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec onc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Rainier Clin Res Ctr Inc, Renton, Washington
Conditions: Diabetes, Type 2
Register for Updates
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652
Recruiting
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/27/2024
Locations: Research Site, Seattle, Washington
Conditions: Heart Failure and Impaired Kidney Function
Register for Updates
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588
Recruiting
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with HNSCC (Head and Neck Squamous Cell Carcinoma)
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: GSK Investigational Site, Tacoma, Washington
Conditions: Neoplasms, Head and Neck
Register for Updates
TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia
NCT06088888
Recruiting
The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Fred Hutchinson Cancer Center, Seattle, Washington
Conditions: Chronic Myelogenous Leukemia
Register for Updates
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266
Recruiting
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/27/2024
Locations: Research Site, Auburn, Washington
Conditions: NSCLC
Register for Updates
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798
Recruiting
This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer (metastatic or locally advanced disease not amenable to curative treatment) who have not previously received a systemic non-hormonal anti-cancer therapy in the adva... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Swedish Cancer Institute - Edmonds Campus, Edmonds, Washington
Conditions: Locally Advanced or Metastatic Breast Cancer
Register for Updates
A Study of Baricitinib (LY3009104) in Children With COVID-19
NCT05074420
Recruiting
The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
Gender:
All
Ages:
Between 2 years and 18 years
Trial Updated:
05/27/2024
Locations: MultiCare Health System, Tacoma, Washington
Conditions: Covid19, Corona Virus Infection
Register for Updates
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226
Recruiting
The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Providence Regional Cancer Partnership, Everett, Washington
Conditions: Cancer
Register for Updates
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
NCT04336722
Recruiting
Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy.
Gender:
All
Ages:
111 days and below
Trial Updated:
05/27/2024
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Biliary Atresia
Register for Updates
A Study of Baricitinib in Participants With Rheumatoid Arthritis
NCT04086745
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Arthritis Northwest, PLLC, Spokane, Washington
Conditions: Rheumatoid Arthritis
Register for Updates